Ubrelvy (Ubrogepant) for Migraine

Overview
Ubrelvy is approved by the U.S. Food and Drug Administration (FDA) to prevent migraine in adults. Ubrelvy is also referred to by its drug name, Ubrogepant.

Ubrelvy is a member of a new class of drugs called calcitonin gene-related peptide receptor (CGRP-R) antagonists. Ubrelvy is believed to work by interfering with CGRP, a substance that dilates blood vessels and contributes to pain signals and inflammation.

How do I take it?
Ubrelvy is taken as needed, up to 200 mg a day.

Ubrelvy comes in tablet form.

Side effects
The FDA-approved label for Ubrelvy lists common side effects including nausea and sleepiness.

Because Ubrelvy is a new drug, its long-term effects are not yet known.

For more details about this treatment, visit:

Ubrelvy – AbbVie
https://www.ubrelvy.com/